Latest filing published 29 Feb 2012 for EPIRUS Biopharmaceuticals, Inc..
Insider track record
No signal scores available.
Christopher C. Gallen: trading record in brief
Christopher C. Gallen discloses dealings in EPIRUS Biopharmaceuticals, Inc. to SEC (Form 4). The record holds 4 filings, for trades running from 1 January 2010 to 29 February 2012.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
On 29 February 2012 came the latest disclosure, a share grant in EPIRUS Biopharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Christopher C. Gallen
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 350,000 shares0Common StockSEC:0001181431-12-012912:0
- 106,073 shares@ US$1.11Common StockSEC:0001181431-10-013351:0
- 253,253 shares0Common StockSEC:0001181431-10-013351:1
- 978,291 shares0Common StockSEC:0001181431-10-001234:0
4 of 4 declarations
